Heart failure & cardiomyopathies
Primary medication adherence in Medicare beneficiaries prescribed sacubitril-valsartan or renin-angiotensin system blockers for heart failure with reduced ejection fraction
Main findingResult — go to the resultAdjusted odds ratio 1.32 95% CI 0.63–2.73Authors' conclusion
In this small, single-center cohort study of Medicare beneficiaries with HFrEF, there was no difference in primary medication adherence among individuals newly prescribed sacubitril-valsartan and those newly prescribed generic ACE-Is or ARBs, although it took sacubitril-valsartan prescription recipients longer to fill their medication.
Study context
- Population
- Medicare beneficiaries with heart failure with reduced ejection fraction (HFrEF), large integrated health care system in Boston
- Participants
- 50 / 231 / 364
- Exposure
- Sacubitril-valsartan vs generic ACEi or ARB
- Sacubitril-valsartann = 50
- ACE-I or ARBn = 231reference
- Switchn = 364
- Outcome
- Proportion filling first prescription for any ARNI, ACEi or ARB (primary adherence)
- Follow-up
- 90 days
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Adjusted odds ratio
1.32
95% CI 0.63–2.73
P = 0.51
Events by group
Sacubitril-valsartanvs ACE-I or ARB
adjusted OR 1.32 (95% CI 0.63–2.73); P = 0.51
Observational data: associations, not effects.
Secondary outcomes
Mean, days
| Outcome | Sacubitril-valsartan | ACE-I or ARB | P value |
|---|---|---|---|
| Mean time to first fillSacubitril-valsartan vs ACE-I or ARB | 18 | 9 | P < 0.001 |
Original publication
Primary medication adherence in Medicare beneficiaries prescribed sacubitril-valsartan or renin-angiotensin system blockers for heart failure with reduced ejection fraction. Am Heart J. Published 3 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →